Safety of modern oral contraceptives [1]

Lancet

Volumn 347, Issue 8996, 1996, Pages 257-260

  Simpson, A J L ^a   Elstein, M ^a   Henzl, M R ^a   Johannisson, E ^a   Bromham, D R ^a   Donnelly, R J ^a  

^a Society Advancement of Contraception   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; ESTROGEN DERIVATIVE; GESTAGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE;

DRUG SAFETY; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; RISK; THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; NOTE; THROMBOPHLEBITIS; DRUG APPROVAL; DRUG SURVEILLANCE PROGRAM; POSTMARKETING SURVEILLANCE; SAFETY;

CONTRACEPTIVES, ORAL; DESOGESTREL; FEMALE; HUMANS; NORPREGNENES; PROGESTERONE CONGENERS; THROMBOPHLEBITIS; ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG APPROVAL; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY;

EID: 0030046530     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90432-8     Document Type: Letter

References (14)

1. Editorial. Sensible alerts Lancet 346 1995 1569 1570
2. Hg Jick Ss Jick V. Gurovitz W. Myers C. Vasilakis Risk of idiopathic cardiovascular disease and non fatal thromboembolism in women using oral contraceptive with differing gestagen components Lancet 345 1995 1589 1592
3. Kwm Bloemenkamp Fr Rosendaal Fm Helmerhorst Hr Buller Jp Vandenbroucke Enhancement of factor V Leiden mutation on risk of deep vein thrombosis associated with oral contraceptives containing third-generation progestagen Lancet 346 1995 1593 1596
4. Wo Spitzer Ma Lewis Laj Heinemann M. Thurgood Kd Macrae Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study BMJ 312 1996 83 88
5. Ma Lewis Wo Spitzer Laj Heinemann Kd Macrae R. Bruppacher M. Thorogood Third generation oral contraceptives and risk of myocardial infarction: an international case-control study BMJ 312 1996 88 90
6. C. Djerassi L. Miramontes G. Rosenkranz The synthesis of 19-norprogesterone steroids XXII J Am Chem Soc 73 1951 3540
7. Ai Csapo Cr Pinto-Dantas The cyclic activity of the non-pregnant human uterus Fertil Steril 17 1966 34 48
8. Jj Stepan J. Pospichal V. Schreiber J. Presl The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethindrone Calc Tissue Int 45 1989 273 280
9. Rm Kraus Dl Tribble Oral contraceptives and plasma lipoprotein metabolism D. Shoupe Fp Haseltine Contraception 1993 Springer New York 34 41
10. Ra Edgren Issues in animal pharmacology Jw Goldzieher Pharmacology of the contraceptive agents 1994 Raven New York 81 97
11. Editorial. Sensible alerts Lancet 346 1995 1569
12. N. Weiss Third-generation oral contraceptives: how risky? Lancet 346 1995 1570
13. R. Farmer Td Preston The risk of venous thromboembolism associated with low oestrogen oral contraceptives J Obstet Gynaecol 15 1995 195 200
14. V. Choo EU agency asks for more data on oral contraceptives Lancet 346 1995 1219